A triazole drug suspension and its preparation method and use
By adjusting the ratio of itraconazole and surfactant, a high-stability suspension was prepared, which solved the problems of low stability and bioavailability of triazole drugs, and achieved rapid absorption of itraconazole in the lungs and Slow release improves the effectiveness of treating lung diseases and the safety of medication.
Patent Information
- Application Number
- CN202411097044.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-12
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2044-08-12
AI Technical Summary
The existing triazole antifungal drug suspensions have poor stability and low bioavailability, resulting in unstable therapeutic effects, and the oral form has fluctuations in systemic exposure, making it difficult to effectively treat lung diseases.
By adjusting the ratio of itraconazole and surfactant, a suspension with high stability is prepared to ensure the particle size distribution and free drug concentration of itraconazole. High-pressure homogenization and other technologies are used to form an appropriate drug storage , achieve rapid absorption and slow release, and reduce the frequency of dosing.
It achieves rapid absorption and continuous release of itraconazole at the target site, improves the therapeutic effect, reduces systemic exposure, enhances the safety of medication, and has the therapeutic effect in diseases such as pulmonary fibrosis and aspergillosis.
Smart Images

Figure CN118634190B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of pharmaceutical preparations, and specifically relates to a triazole drug suspension, a preparation method and uses thereof, and in particular to an itraconazole suspension for inhalation for treating lung diseases, a preparation method and uses thereof. Background Art
[0002] Pulmonary fibrosis (PF) is a serious lung disease with unknown etiology and irreversible course. The main clinical manifestations are dyspnea, dry cough, fatigue, easy fatigue, etc. Medical imaging tests show that patients with pulmonary fibrosis have a large amount of collagen fiber deposition, a large amount of alveolar loss, changes in normal lung tissue structure, loss of gas exchange function, and eventually death from respiratory failure. Due to limited treatment drugs, the prognosis and quality of life are poor. The 5-year overall survival rate of patients with pulmonary fibrosis is less than 50%. According to statistics, 80% of patients who die from the disease each year in the world are related to pulmonary fibrosis. There is currently no specific treatment method, and the main treatment is anti-inflammatory, anti-fibrotic, immunosuppressant and glucocorticoid treatment for different causes of the disease.
[0003] Allergic bronchopulmonary aspergillosis (ABPA) is an allergic inflammatory disease caused by the body's allergy to Aspergillus fumigatus. In my country, ABPA often occurs in patients with bronchial asthma (abbreviated as asthma), and clinical manifestations include asthma, recurrent lung shadows, and may be accompanied by bronchiectasis. In Europe and the United States, pulmonary cystic fibrosis complicated by ABPA is more common. Due to the general lack of understanding of the disease among clinicians, misdiagnosis or missed diagnosis is often caused, and the treatment effect is unstable. The best treatment for ABPA should achieve early control of symptoms, prevent the progression of bronchiectasis, and reduce the risk of future aggravation with the least possible adverse events. Glucocorticoids are currently the main drug for the treatment of ABPA. The use of antifungal drugs in the treatment of ABPA can reduce the body's immune response by reducing the fungal load to reduce antigen stimulation, thereby eliminating or reducing the patient's need for glucocorticoids.
[0004] Triazole antifungal drugs, such as voriconazole, itraconazole, and posaconazole, can be considered for the treatment of pulmonary diseases. However, oral triazole drugs have problems such as low bioavailability, high liver metabolism, and / or drug interactions, resulting in fluctuations in systemic exposure.
[0005] When developing a suspension of triazole antifungal drugs for nebulizers, the inventors of the present application found that the existing suspension of triazole antifungal drugs had poor stability, and the drug particles would obviously agglomerate after being placed at room temperature for 3 months, making it unsuitable for medicinal use. Therefore, a "suspension of triazole antifungal drugs for nebulizers" (see Chinese patent application CN111658610 A) was provided. However, although the drug had good physical stability, the effects of itraconazole suspensions meeting the requirements prepared in different prescriptions according to "suspension of triazole antifungal drugs for nebulizers" (CN111658610 A) on the bleomycin-induced rat pulmonary fibrosis model were quite different. Summary of the invention
[0006] In order to overcome the defects of the prior art, the present invention provides a triazole drug suspension and a preparation method and use thereof. The suspension of the present invention has high stability and can be stored for more than 3 years at room temperature. At the same time, the present invention adjusts the ratio of active ingredients and surfactants in the suspension, the content of free drugs in the preparation and the particle size distribution of particulate drugs, so that after inhalation administration, the drug is quickly absorbed and effective at the target site, and can be released slowly and continuously, while maintaining the therapeutic dose, reducing the frequency of administration and improving the safety of medication. In addition, the present invention is combined with an appropriate preparation process to make the preparation effect better.
[0007] In order to achieve the above-mentioned object of the invention, the present invention adopts the following technical solutions:
[0008] In one aspect, the present invention provides a triazole drug suspension, comprising a therapeutically effective amount of itraconazole and a surfactant, wherein the mass ratio of the itraconazole to the surfactant is 5:1 to 15:1.
[0009] Preferably, the suspension comprises one or more of the following technical features:
[0010] A1) the suspension further comprises water as a solvent;
[0011] A2) the suspension further comprises an osmotic pressure regulator;
[0012] A3) the suspension further comprises a metal complexing agent;
[0013] A4) the suspension further comprises a pH adjuster;
[0014] A5) The particle size of itraconazole is D 10 Greater than or equal to 0.5μm, D 50 1.5~3.5μm, D 90 Less than or equal to 6.0μm;
[0015] A6) the mass ratio of the itraconazole to the surfactant is 5:1 to 12:1;
[0016] A7) the concentration of free itraconazole in the suspension is not less than 0.04 μg / ml;
[0017] A8) The surfactant is selected from one or more of lecithin, Tween and Span surfactants;
[0018] A9) the osmotic pressure molar concentration of the suspension is 260-330 mOsmol / kg;
[0019] A10) The pH value of the suspension should be 5.5-6.5;
[0020] A11) The suspension is itraconazole suspension for inhalation.
[0021] Preferably, the suspension comprises one or more of the following technical features:
[0022] B1) In feature A2), the osmotic pressure regulator is sodium chloride or glucose;
[0023] B2) In feature A3), the metal complexing agent is selected from one or more of disodium ethylenediaminetetraacetate (EDTA), trisodium ethylenediaminetetraacetate, tetrasodium ethylenediaminetetraacetate or sodium calcium ethylenediaminetetraacetate;
[0024] B3) In feature A3), the mass of the metal complexing agent is 0% to 0.02% of the total mass of the suspension;
[0025] B4) In feature A4), the pH adjuster is selected from one or more of NaOH / HCl, citric acid / sodium citrate or sodium dihydrogen phosphate / disodium hydrogen phosphate;
[0026] B5) In feature A5), the particle size of itraconazole is D 10 0.8~1.2μm, D 50 1.5~2.6μm, D 90 2.8~5.5μm;
[0027] B6) In feature A6), the mass ratio between the itraconazole and the surfactant is 8:1 to 12:1;
[0028] B7) In feature A7), the concentration of free itraconazole in the suspension should be 0.08 μg / ml to 0.4 μg / ml.
[0029] B8) In feature A8), the Tween is selected from one or more of Tween-20 and Tween-80.
[0030] Preferably, in feature B3), the mass of the metal complexing agent is 0.008% to 0.012% of the total mass of the suspension.
[0031] Preferably, in feature B7), the Span is selected from Span-20.
[0032] On the other hand, the present invention provides a method for preparing the triazole drug suspension, comprising first mixing a surfactant and itraconazole, sterilizing, cooling, and homogenizing to obtain the itraconazole suspension.
[0033] Preferably, the above preparation method includes one or more of the following technical features:
[0034] D1) before the first mixing, the surfactant is first dissolved in water to obtain a dispersion medium;
[0035] D2) The particle size of the itraconazole 90 Less than 10 μm;
[0036] D3) The sterilization is moist heat sterilization, and the F0 value should be ≥8;
[0037] D4) The sterilization conditions include sterilization at 121°C for no less than 8 minutes and sterilization at 115°C for no less than 30 minutes;
[0038] D5) cooling after the sterilization;
[0039] D6) the homogenization is selected from one or more of high pressure homogenization, microfluidization or media grinding;
[0040] D7) After the first mixing, the method further includes performing a second mixing with an auxiliary material solution.
[0041] Preferably, the above preparation method includes one or more of the following technical features:
[0042] E1) In feature D4), the sterilization conditions are 121°C for 8-20 min and 115°C for 30 min;
[0043] E2) In feature D5), the cooling temperature is not higher than 50°C;
[0044] E3) In feature D6), the homogenization is micro-jet high-pressure homogenization, and the homogenization pressure is 700-1000 bar.
[0045] In another aspect, the present invention provides use of the above triazole drug suspension or the triazole drug suspension obtained by the preparation method in preparing drugs for preventing and / or treating lung or respiratory diseases.
[0046] Preferably, the lung or respiratory disease is selected from one or more of pulmonary fibrosis, pulmonary aspergillosis, fungal sensitization to asthma, respiratory fungal infection, lung fungal infection, fungal infection of organ transplantation or chronic idiopathic cough.
[0047] The content of the present invention is described in detail below.
[0048] Considering the existing antifungal drugs have poor stability, slow onset, possible hidden dangers in drug safety, etc. The present invention develops an itraconazole suspension and a preparation method and use thereof.
[0049] In certain technical schemes, the present invention provides an itraconazole suspension, which comprises a therapeutically effective amount of itraconazole, a surfactant, a solvent water, an osmotic pressure regulator, a metal complexing agent, and a pH regulator, wherein the mass ratio between the itraconazole and the surfactant is 5:1 to 15:1.
[0050] Preferably, the mass ratio between the itraconazole and the surfactant is 8:1-12:1.
[0051] Preferably, the particle size of itraconazole is D 10 Greater than or equal to 0.5μm, D 50 1.5~3.5μm, D 90 Less than or equal to 6.0μm;
[0052] Preferably, the particle size of itraconazole is D 10 0.8~1.2μm, D 50 1.5~2.6μm, D 90 2.8~5.5μm.
[0053] Preferably, the concentration of free itraconazole in the suspension is not less than 0.04 μg / ml. After administration by inhalation, the free drug in the suspension can be quickly absorbed and effective, while the granular drug forms a "drug reservoir" at the target site, which can slowly release the drug, thereby reducing the frequency of administration and improving the safety of medication.
[0054] Preferably, the concentration of free itraconazole in the suspension should be 0.08 μg / ml to 0.5 μg / ml.
[0055] The type of surfactant described in the present invention can be selected according to the conventional practice in the art. The present invention preferably uses a non-ionic surfactant, and more preferably one or more selected from lecithin, Tween, and Span surfactants.
[0056] Preferably, the Tween is selected from one or more of Tween-20 and Tween-80.
[0057] Preferably, the Span is selected from Span-20.
[0058] If necessary, the suspension of the present invention may contain an auxiliary material as an osmotic pressure regulator to keep the osmotic pressure molar concentration of the prescribed drug solution consistent with the osmotic pressure molar concentration range of human blood. Commonly used osmotic pressure regulators are sodium chloride, glucose, etc., and it is preferred to maintain the osmotic pressure molar concentration of the drug solution in the range of 260-330 mOsmol / kg.
[0059] If necessary, the suspension of the present invention may contain a metal complexing agent. Suitable metal complexing agents include disodium ethylenediaminetetraacetate, trisodium ethylenediaminetetraacetate, tetrasodium ethylenediaminetetraacetate, and sodium calcium ethylenediaminetetraacetate. Disodium ethylenediaminetetraacetate is preferred. If a metal complexing agent is present, it is generally present in an amount of about 0% to 0.02% (w / w) of the total mass of the suspension, and more preferably in an amount of about 0.008% to 0.012% of the total mass of the suspension. In the case where the metal complexing agent is disodium ethylenediaminetetraacetate, it is preferably present in an amount of 0.01% (w / w) of the total mass of the suspension. The preparation of the present invention has a pH of 5.5 to 6.5. The pH can be adjusted with a pH adjusting agent such as NaOH / HCl, citric acid / sodium citrate or sodium dihydrogen phosphate / disodium hydrogen phosphate. A preferred pH adjusting agent for the preparation of the present invention is a combination of citric acid and sodium citrate.
[0060] Preferably, the suspension of the present invention is an itraconazole suspension for inhalation.
[0061] Preferably, the itraconazole suspension for inhalation of the present invention can be used with an atomizing device that generates an aerosol using compressed air, ultrasound or a vibrating mesh.
[0062] The itraconazole suspension for inhalation of the present invention enters the lungs after being administered through an atomizing device, and the drug in a free state in the aerosol can be directly absorbed by the target site and take effect quickly. At the same time, the drug particles in the aerosol can be deposited at the target site to form a "drug reservoir", and the drug in the reservoir is slowly dissolved and released and then absorbed by the target site, so that the drug can take effect continuously at the target site.
[0063] The inhaled itraconazole suspension of the present invention can be used for lung or respiratory diseases, such as pulmonary fibrosis, pulmonary aspergillosis, fungal sensitization asthma, prevention and treatment of early aspergillus infection after lung transplantation, respiratory fungal infection and the like.
[0064] In certain embodiments, the method for preparing the above-mentioned itraconazole suspension of the present invention is prepared by high-pressure homogenization, microfluidization, media grinding and other techniques, comprising the following steps:
[0065] (1) Take D 90APIs with a diameter of less than 10 μm, the particle size of which can be controlled by chemical synthesis, air flow milling and other technical means;
[0066] (2) dispersing the active ingredient itraconazole in the raw material drug prepared in step (1) in an aqueous solution containing part or all of the prescribed amount of a surfactant to prepare a main drug concentrated solution;
[0067] (3) mixing the main drug concentrated solution prepared in step (2) with the auxiliary material solution to obtain a primary suspension; the auxiliary material solution here is a solution prepared by adding water to the remaining auxiliary materials;
[0068] (4) Sterilize the initial suspension obtained in step (3); the F0 value should be ≥ 8 to obtain a sterile suspension;
[0069] (5) Dispersing the sterile suspension obtained in step (4) by high-pressure homogenization, microfluidization, medium grinding and other techniques to obtain the product.
[0070] Preferably, in step (4), the sterilization conditions include sterilization at 121°C for not less than 8 min, preferably 8-20 min.
[0071] Preferably, in step (4), the sterilization conditions include sterilization at 115°C for not less than 30 minutes.
[0072] Preferably, in step (5), the high-pressure homogenization may be performed using, for example, a microfluidics device from Microfluidics International Corporation of the United States, with a homogenization pressure of 700-1000 bar.
[0073] In certain embodiments, the present invention provides the use of the above-mentioned itraconazole suspension in the preparation of a method for preventing and / or treating lung or respiratory diseases, such as pulmonary fibrosis, pulmonary aspergillosis, fungal-sensitized asthma, preventing and treating early Aspergillus infection after lung transplantation, and respiratory fungal infection.
[0074] Preferably, the pulmonary or respiratory disease is selected from pulmonary fibrosis, pulmonary aspergillosis, fungal sensitized asthma, respiratory fungal infection, lung fungal infection, organ transplant fungal infection and chronic idiopathic cough.
[0075] Compared with the prior art, the present invention has the following beneficial effects:
[0076] (1) The present invention provides a new, safe and effective suspension of itraconazole. The preparation can achieve high-dose administration in a short period of time by inhalation, presenting a higher dose of lung deposition to increase the pharmacological (preventive or therapeutic) effect, while reducing systemic exposure.
[0077] (2) The particle size of the particles in the itraconazole suspension of the present invention is within a specific range, and the particle size stability during storage can be guaranteed, thereby ensuring the drug administration effect.
[0078] (3) Unexpectedly, we found that itraconazole can take effect quickly at the target site and form a drug depot, which is continuously dissolved and released into the lung tissue, possibly due to the appropriate free active drug concentration in the prescription and the deposition of active drug particles of appropriate size in the lungs. This can prolong the duration of action in the lungs and reduce the frequency of long-term use and repeated dosing.
[0079] (4) The prescription and preparation method of the present invention can be produced in large quantities and continuously, and can be easily realized in industrial production.
[0080] (5) The inhaled itraconazole suspension of the present invention has achieved good results in the treatment of non-clinical animal models of pulmonary fibrosis and pulmonary Aspergillus fumigatus infection, providing a new dosing regimen for treatment in this field. BRIEF DESCRIPTION OF THE DRAWINGS
[0081] The present invention will be further described below in conjunction with the accompanying drawings.
[0082] Figure 1 Drug-time curve after multiple inhalation administration in dogs, where D1, D2, D3, D4, D5, and D6 represent the 1st, 2nd, 3rd, 4th, 5th, and 6th inhalation administration, respectively;
[0083] Figure 2 Itraconazole concentrations (ng / g) in various tissues (heart, liver, spleen, kidney, and lung) 120 h after the last dose during multiple dosing in dogs;
[0084] Figure 3 Alleviation of pathological changes of pulmonary fibrosis in BLM mouse model (H&E staining), including Figure A-control group, Figure B-model group, Figure C-inhaled itraconazole suspension group, Figure D-oral administration of itraconazole group, magnification: 40×;
[0085] Figure 4 Reduced inflammatory cell infiltration in lung tissue of BLM mouse model (H&E staining), including Figure A-control group, Figure B-model group, Figure C-inhaled itraconazole suspension group, Figure D-oral administration of itraconazole group, magnification: 400×;
[0086] Figure 5 Alleviate the pathological changes of pulmonary fibrosis in the Silica mouse model (H&E staining), where Figure A-control group, Figure B-model group, Figure C-inhaled itraconazole suspension group, Figure D-oral administration of itraconazole group, magnification: 40×;
[0087] Figure 6Reduced inflammatory cell infiltration in lung tissue of Silica mouse model (H&E staining), including Figure A-control group, Figure B-model group, Figure C-inhaled itraconazole suspension group, Figure D-oral administration of itraconazole group, magnification: 400×;
[0088] Figure 7 14-day survival curve of mice in the mouse pulmonary Aspergillus fumigatus infection model induced by Aspergillus fumigatus. DETAILED DESCRIPTION
[0089] The technical scheme of the present invention will be further described in detail below in conjunction with specific embodiments. It should be understood that the following embodiments are only exemplary descriptions and explanations of the present invention, and should not be construed as limiting the scope of protection of the present invention. All technologies realized based on the above content of the present invention are included in the scope that the present invention is intended to protect.
[0090] Example 1: Itraconazole suspension
[0091] Prescription A:
[0092] Itraconazole: 250 g itraconazole;
[0093] Surfactant: 16.7 g Tween 80;
[0094] Osmotic pressure regulator: 850g sodium chloride;
[0095] Metal complexing agent: 10 g disodium edetate;
[0096] pH adjuster: 27g citric acid and 400g sodium citrate;
[0097] Water for injection: up to 100kg.
[0098] Wherein, the mass ratio between the itraconazole and the surfactant is 15:1.
[0099] Preparation method:
[0100] (1) Dissolve 16.7 g of Tween 80 in 1000 ml of water for injection to obtain a dispersion medium;
[0101] (2) 250 g of itraconazole API (D 90 about 8.2 μm) is wetted and dispersed in the medium of step (1) to obtain a concentrated solution;
[0102] (3) Add about 90 kg of water for injection into a preparation tank, add 850 g of sodium chloride, 10 g of disodium edetate, 27 g of citric acid and 400 g of sodium citrate, and stir until completely dissolved to obtain an excipient solution;
[0103] (4) While stirring, add the concentrated solution prepared in step (2) to the auxiliary material solution prepared in step (3), add water to 100 kg, and stir to mix evenly to obtain a primary suspension;
[0104] (5) Sterilize the initial suspension obtained in step (4) at 121°C for 15 min, cool to below 30°C, and homogenize at 1162 rpm for 30 min to obtain a sterile coarse suspension;
[0105] (6) The sterile crude suspension obtained in step (5) was subjected to microfluidization high-pressure homogenization at a homogenization pressure of 1000 bar and the number of cycles was 2 to obtain an itraconazole suspension for inhalation.
[0106] Example 2: Itraconazole suspension
[0107] Prescription B:
[0108] Itraconazole: 250 g itraconazole;
[0109] Surfactant: 12.5 g Tween 80;
[0110] Osmotic pressure regulator: 850g sodium chloride;
[0111] Metal complexing agent: 10 g disodium edetate;
[0112] pH adjuster: 27g citric acid and 400g sodium citrate;
[0113] Water for injection: up to 100kg
[0114] Wherein, the mass ratio between the itraconazole and the surfactant is 20:1.
[0115] Preparation method:
[0116] (1) Dissolve 12.5 g of Tween 80 in 1000 ml of water for injection to obtain a dispersion medium;
[0117] (2) 250 g of itraconazole API (D 90 about 8.2 μm) is wetted and dispersed in the medium of step (1) to obtain a concentrated solution;
[0118] (3) Add about 90 kg of water for injection into a preparation tank, add 850 g of sodium chloride, 10 g of disodium edetate, 27 g of citric acid and 400 g of sodium citrate, stir until completely dissolved, and obtain an excipient solution;
[0119] (4) While stirring, add the concentrated solution prepared in step (2) to the auxiliary material solution prepared in step (3), add water to 100 kg, and stir to mix evenly to obtain a primary suspension;
[0120] (5) Sterilize the initial suspension obtained in step (4) at 121°C for 15 min, cool to below 30°C, and homogenize at 1162 rpm for 30 min to obtain a sterile coarse suspension;
[0121] (6) The sterile crude suspension obtained in step (5) was subjected to microfluidization high-pressure homogenization at a homogenization pressure of 900 bar and one cycle to obtain an itraconazole suspension for inhalation.
[0122] Example 3: Pharmacokinetic test of the suspensions of Example 1 and Example 2
[0123] This example investigates the pharmacokinetic test of the above-mentioned itraconazole suspension for inhalation in rats after a single inhalation administration, and makes a comparison.
[0124] Instruments and equipment:
[0125]
[0126] Experimental animals: SD rats, SPF grade, 200-250g
[0127] Test drug: itraconazole suspension for inhalation of Example 1 and Example 2 (i.e., prescription A and prescription B)
[0128] Grouping and dosing: Each group had 8 rats, half of them were male and half were female. The same dose (1.5 mg / kg) was nebulized with different prescriptions for the same time (nebulization inhalation for 30 min). The drug was administered by nebulization inhalation once.
[0129] Detection index: drug concentration in rat plasma at different times after administration. Blood was collected before administration and at 0.083 h, 0.25 h, 0.5 h, 0.75 h, 1 h, 1.5 h, 2 h, 4 h, 6 h, 8 h, 12 h, 24 h, 48 h, 72 h, 96 h, and 120 h after administration.
[0130] Experimental results: The non-compartmental model was used to analyze the blood drug concentration-time data using Phoenix WinNonlin software (version 7.0) to calculate the pharmacokinetic parameters. The results are shown in Table 1 below.
[0131] Table 1
[0132]
[0133] According to Table 1 above, it can be seen that the statistical analysis of pharmacokinetic parameters showed that the C of rats in group A was max and AUC last Both were significantly higher than those in the rats in prescription B group (P<0.05).
[0134] However, based on a slight change in the mass ratio between the itraconazole and the surfactant and a slight change in the preparation process parameters, C max (ng / mL) and AUC last (h*ng / mL) has such a large change, the inventors speculate that there may be other parameters in the preparation that will affect the above C max (ng / mL) and AUC last (h*ng / mL) has an impact, therefore, the inventors studied other parameters in the preparation, especially the particle size distribution of the drug and the free drug in the preparation, as shown in Example 4.
[0135] Example 4: Drug Particle Size Distribution and Free Drug Concentration in the Preparations in Example 1 and Example 2
[0136] In order to explore the deeper reasons for the difference in product effects between Examples 1 and 2, the inventors measured the drug particle size distribution of the itraconazole suspension for inhalation and the free drug concentration in the preparations of the two groups of Examples. The implementation method and results are as follows:
[0137] Referring to the Particle Size and Particle Size Distribution Determination Method of the Fourth General Rule of the 2020 Chinese Pharmacopoeia, the particle size distribution of the drug in the suspension preparation was determined using the SYMPATICHELOS / BR-multi laser particle size analyzer. At the same time, the inhalation itraconazole suspension was placed at 25°C ± 2°C and 40% RH ± 5% RH for 1 month, the suspension was centrifuged at 10000 rpm for 10 min, the supernatant was taken, filtered through a 0.22 μm filter membrane, and the subsequent filtrate was taken for HPLC analysis to determine and calculate the concentration of free drugs in the sample. The results are shown in Table 2.
[0138] Table 2
[0139]
[0140] From the above experimental results, it can be seen that although the D of the suspensions of prescription A and prescription B 50 Both are within the range of 1.5 to 5.5 described in CN111658610 A, but prescription B shows a poor C max and AUC last As a result, due to C max and AUC last Parameters are important indicators for evaluating the absorption rate and degree of drugs in the body, and reflect the exposure characteristics of drugs in the body. Combined with the differences in the particle size distribution and free drug concentration test results of the two examples, the inventors analyzed that the free drug concentration and drug particle size distribution in the suspension must be controlled within an appropriate range in order to obtain the ideal in vivo effect. Therefore, the inventors are considering further studying the above phenomenon.
[0141] Example 5: Preliminary investigation of the effects of drug particle size distribution and free drug concentration in the preparation on the efficacy
[0142] According to the ratio of itraconazole to surfactant of 5:1, 10:1 and 12:1 respectively, the same prescription and process as in Example 1 were used to prepare the prescriptions C, D and E of itraconazole suspension for inhalation. 90 The diameter is about 5.3 μm, the homogenization pressure is 700 bar, and the number of cycles is 2. The particle size distribution and free drug concentration of the drug in the sample were investigated, and the pharmacokinetic test of single inhalation administration in rats was carried out using samples of prescriptions C, D and E. The measured drug particle size distribution and free drug concentration in the preparation are shown in Table 3. The pharmacokinetic results of administration are shown in Table 4.
[0143] Table 3
[0144]
[0145] Table 4
[0146]
[0147] The pharmacokinetic results of single inhalation administration in rats showed that the AUC of formulations C, D and E last The results were basically the same, but the C of prescription D and E max There is a significant difference from the formulation C. By comparing the in vitro data analysis, it is considered that the free drug concentration in the preparation affects the C in rats. max .
[0148] Furthermore, the itraconazole and surfactant were mixed in a ratio of 8:1, and the same formulation and process as in Example 1 were used to prepare a formulation F of itraconazole suspension for inhalation. 90 The diameter is about 5.3 μm, the homogenization pressure is 700 bar, and the number of cycles is 2. The particle size distribution of the drug and the concentration of free drug in the sample were investigated, and the pharmacokinetic test of single inhalation administration in rats was carried out using the sample of prescription F, and the results were compared with those of prescription B and prescription D. The measured drug particle size distribution and free drug concentration in the preparation are shown in Table 5. The pharmacokinetic results of administration are shown in Table 6.
[0149] Table 5
[0150]
[0151] Table 6
[0152]
[0153] The pharmacokinetic results of single inhalation administration in rats showed that the C of Formulation B and Formulation D was significantly lower than that of Formulation F.max The results were somewhat different, and the AUC of prescription D and prescription F last There is a significant difference from formulation B. Compared with the in vitro data analysis, it is considered that the particle size distribution of the drug in the preparation affects the AUC in rats last .
[0154] Example 6: Determination of free drug concentration
[0155] A bleomycin (BLM)-induced rat pulmonary fibrosis model was established to investigate the efficacy of the itraconazole suspension of the present invention via inhalation.
[0156] Instruments and equipment:
[0157]
[0158] Experimental animals: SD rats, SPF grade, weight 180-200 g, male
[0159] Model establishment: Rats were anesthetized with isoflurane and fixed in supine position. The neck skin was disinfected, the neck skin was cut, the trachea was separated, and 10 mg / mL BLM solution was extracted with an aerosol pulmonary administration kit at a dose of 20 μL / 100 g and quickly sprayed into the rat lungs through the trachea. The skin was sutured and disinfected. The blank control group was sprayed with the same amount of normal saline into the airway.
[0160] Experimental drug: Itraconazole suspension for inhalation (Formulation B, Formulation C, Formulation D)
[0161] Grouping and administration: The animals were randomly divided into 5 groups (control group, model group, prescription B, prescription C, prescription D), with 10 animals in each group. Different groups were nebulized with the same dose (1.5 mg / kg) and the same time (nebulization inhalation for 12 min), and the drug was administered by nebulization inhalation. The drug was administered starting on the day of modeling (recorded as Day 0) and was administered once a day for 21 consecutive days.
[0162] Detection indicators: On the second day after the last administration, the rats were anesthetized and bled to death, the trachea was intubated, the left lung and part of the right lung were ligated, and lavage was performed with 1 mL of bronchoalveolar lavage fluid (BALF), which was repeated twice. The lavage fluids from the three times were combined and mixed evenly. The white blood cells were counted under a microscope, and then centrifuged at 2000 rpm for 10 min. The precipitate was used for smear, dried at room temperature, and stained with Wright-Giemsa. 200 cells were counted under a microscope, and the numbers of neutrophils, lymphocytes, and macrophages were recorded respectively.
[0163] Lung tissue was obtained, and the upper part of the left lung was fixed with 10% neutral buffered formalin solution for pathological sectioning, H&E staining and Masson's staining, and semi-quantitative analysis was performed; the lower part was stored in a -80℃ refrigerator, and the q-PCR method was used to detect the expression of IL-1β, IL-6, CXCL1, TIMP-1, TGF-β1, α-SMA, Fibronectin, and COL1A1 mRNA in lung tissue; the unlavaged right lung was stored in a -80℃ refrigerator, and ELISA was used to detect the expression of IL-8, IL-1β, IL-6, and TIMP-1 proteins; the remaining lung tissue was used to determine the content of hydroxyproline. Some key test results are shown in Table 7.
[0164] Table 7 Effect of inhaled itraconazole suspension on bleomycin-induced idiopathic pulmonary fibrosis in rats
[0165]
[0166] Note: One-way ANOVA, compared with the control group, # P < 0.001, ## P<0.01; compared with the model group, * P<0.05, ** P<0.01, *** P<0.001.
[0167] The statistical results showed that the inhaled itraconazole suspension prescription B showed that some indicators could alleviate the pulmonary fibrosis of the model rats, while the prescription C and prescription D groups had a significant alleviating effect (P<0.01-0.001). The particle size distribution and free drug concentration results of prescriptions B, C, and D were compared and analyzed, and the free drug concentration in the inhaled itraconazole suspension of the present invention was limited to not less than 0.08μg / ml.
[0168] Example 7: Determination of particle size distribution
[0169] According to the research results of Example 6, the rat pharmacokinetic data results obtained in Example 3, Example 4 and Example 5 were analyzed, and for the bleomycin-induced rat pulmonary fibrosis model, the inhalation administration of the itraconazole suspension of the present invention can have a good therapeutic and preventive effect on the pulmonary fibrosis model. Based on the particle size distribution of the above prescriptions and compared with the particle size distribution of prescription B, the particle size of the itraconazole suspension for inhalation is limited to D 10 Greater than or equal to 0.5μm, D 50 In the range of 1.5~3.5μm, D 90 Less than or equal to 6.0μm.
[0170] Preferably, D 10 为 0.8~1.2μm, D 50 1.5~2.6μm, D90 2.8~5.5μm. Example 8
[0171] The pharmacokinetic test of multiple inhalation administration of the itraconazole suspension of the present invention to dogs was carried out, revealing the dynamic change law of the drug of the present invention in the dog after multiple inhalation.
[0172] Instruments and equipment:
[0173]
[0174] Experimental animals: Beagle dogs, normal grade, 10-11 months old, 8.4-10.8 kg
[0175] Trial drug: Itraconazole suspension for inhalation (Formulation B, Formulation D)
[0176] Grouping and dosing: Each group consisted of 6 Beagle dogs, 3 males and 3 females. The drugs were administered by nebulized inhalation once a day at the same time for 5 consecutive times. Together with the single inhalation pharmacokinetic test, the drugs were administered 6 times in total. The dosage was 1.0 mg / kg.
[0177] Detection indicators: blood drug concentration and drug concentration in various tissues at different administration times. The single inhalation administration of dogs was recorded as the first administration (D 1), and blood was collected before the first and last administration (D 6) and 0.083 h, 0.25 h, 0.5 h, 0.75 h, 1 h, 1.5 h, 2 h, 4 h, 6 h, 8 h, 12 h, 24 h, 48 h, 72 h, 96 h, and 120 h after administration; blood was collected 6 h and 24 h after administration from D 2 to D 5. The non-compartmental model was used to analyze the blood drug concentration-time data using Phoenix WinNonlin software (version 7.0) to calculate the pharmacokinetic parameters, see Table 8 and Figure 1 The drug concentrations in various tissues 120 h after the last administration are shown in Table 9 and Figure 2 .
[0178] Table 8
[0179]
[0180] Table 9
[0181]
[0182] The results of the pharmacokinetic test of multiple inhalation administration in dogs showed that the concentration of itraconazole in the lung tissue was much higher than that in the heart, liver, spleen and kidney tissues after nebulized inhalation of itraconazole suspension, which reflects the advantages of local nebulized inhalation treatment of itraconazole. The comparison results of the inhaled itraconazole suspension prescription B and prescription D showed that the peak concentration of prescription D could be reached quickly (about 4 hours) after administration; after multiple nebulized inhalation administration, the peak concentration gradually increased, tended to a steady state after the 4th to 6th administration, and the peak concentration after the last administration of C max and AUC last Significantly higher than the first dose ( P <0.001); Prescription B reached a peak concentration about 8 hours after administration, and after multiple aerosol inhalation administrations, the peak concentration gradually increased, but basically remained at a low level. The above results suggest that the drug particles deposited in the lungs after aerosol inhalation of the itraconazole suspension of the present invention form a "drug warehouse" at the target site, which can slowly release the drug into the lung tissue, thereby increasing the duration of action in the lungs and reducing the frequency of administration during treatment.
[0183] Example 9: Drug efficacy test example for pulmonary fibrosis
[0184] Bleomycin (BLM)-induced mouse pulmonary fibrosis model and silica-induced mouse pulmonary fibrosis model were established, and the administration of itraconazole by inhalation and oral route was compared, and the efficacy of the itraconazole suspension of the present invention by inhalation route was investigated.
[0185] Instruments and equipment: Same as Example 6.
[0186] 1. Effect on BLM-induced mouse pulmonary fibrosis model
[0187] Experimental animals: ICR mice: SPF grade, weight 22-25 g, female
[0188] Model establishment: Mice were anesthetized with isoflurane, fixed in supine position, the neck skin was disinfected, the neck skin was cut, the trachea was separated, and 1 mg / mL BLM solution was extracted with an aerosol pulmonary administration kit and quickly sprayed into the mouse lungs through the trachea, 25 μL / mouse, the skin was sutured and disinfected. The blank control group was sprayed with normal saline in the airway, 25 μL / mouse.
[0189] Trial drug: Itraconazole suspension for inhalation (Formulation D)
[0190] Grouping and dosing: The animals were randomly divided into 4 groups, with 10 animals in each group. Dosing began on the day of modeling (recorded as Day 0) and was administered once a day for 21 consecutive days. Specific grouping and dosing information is shown in Table 10.
[0191] Table 10
[0192]
[0193] 2. Effects on Silica-induced Mouse Pulmonary Fibrosis Model
[0194] Experimental animals: ICR mice: SPF grade, weight 22-25 g, male
[0195] Model establishment: Mice were anesthetized with isoflurane, fixed in supine position, neck skin disinfected, neck skin cut, trachea separated, 100 mg / mL Silica-normal saline mixture was drawn with a syringe and sprayed into the lungs of mice quickly through the trachea, 50 μL / mouse, skin sutured, and disinfected. Normal saline was sprayed into the airway of the blank control group, 50 μL / mouse.
[0196] Trial drug: Itraconazole suspension for inhalation (Formulation D)
[0197] Grouping and dosing: The animals were randomly divided into 4 groups, with 10 animals in each group. Dosing began on the day of modeling (recorded as Day 0) and was administered once a day for 21 consecutive days. The specific grouping and dosing information are the same as Table 10.
[0198] Detection indicators: On the second day after the last administration, mice were killed by dislocation and bronchoalveolar lavage was performed, and the number of inflammatory cells in bronchoalveolar lavage fluid (BALF) was counted under a microscope; BALF centrifugal sediment smears were stained with Wright-Giemsa, and neutrophils, macrophages and lymphocytes were counted under a microscope; quantitative polymerase chain reaction (q-PCR) was used to detect interleukin (IL)-1β, IL-6, KC (mouse interleukin 8), tissue inhibitor of metalloproteinase (TIMP)-1, transforming growth factor (TGF)-β1, mucin (MUC) 5AC, α-actin (SMA), fibronectin (Fibronectin), collagen (COL) 1A1 in lung tissues mRNA expression; enzyme-linked immunosorbent assay (ELISA) was used to detect the protein levels of KC, IL-1β, IL-6, and TIMP-1 in lung tissue; the hydroxyproline content in lung tissue was detected by microassay; lung tissue was fixed with 10% buffered neutral formalin solution, embedded in paraffin, and sliced. After H&E staining, the Ashcroft scoring method was used to evaluate lung tissue fibrosis and inflammatory cell infiltration. Some key test results are shown in Tables 11 to 12 and Figure 3~Figure 6 .
[0199] Table 11 Effects of different drug administration groups on bleomycin-induced idiopathic pulmonary fibrosis in mice
[0200]
[0201] Note: One-way ANOVA, compared with the control group, # P <0.001,## P <0.01; compared with the model group, * P <0.05, ** P <0.01, *** P <0.001.
[0202] Table 12 Effects of different drug administration groups on silica-induced idiopathic pulmonary fibrosis in mice
[0203]
[0204] Note: One-way ANOVA, compared with the control group, # P <0.001, ## P <0.01; compared with the model group, * P <0.05, ** P <0.01, *** P <0.001.
[0205] Experiments on two whole animal models showed that inhaled itraconazole suspension can significantly reduce the production of fibrotic factors in lung tissue and significantly alleviate fibrotic lesions in lung tissue, which includes the strong anti-inflammatory effect of itraconazole. When the inhaled dose of itraconazole (12.4 mg / kg) is 1 / 2.5 times the oral dose (30 mg / kg), the effect on the model is stronger, indicating that inhaled administration of itraconazole is significantly better than oral administration in terms of efficacy. The results of testing the blood drug concentration and lung tissue drug concentration of rats after inhaled administration and oral administration indicate that the drug can reach the lung tissue (target organ) directly after inhaled administration. When the blood drug concentration is lower than or similar, the lung tissue drug concentration is much higher than that of oral administration. This reflects the advantages of high target organ efficacy of local atomized inhalation in the respiratory tract, low systemic tissue concentration, and reduced adverse reactions.
[0206] Example 10 Anti-Aspergillus fumigatus efficacy test example
[0207] Experimental animals: ICR mice, SPF grade, weight 22-25 g, male
[0208] Model establishment: The model mice were subcutaneously injected with 200 mg / kg cyclophosphamide 2 days before infection (Day -2), and 100 mg / kg cyclophosphamide was subcutaneously injected 1 day before infection (Day -1) to suppress the mouse's own immune system. On the day of infection (Day 0), Aspergillus fumigatus was sprayed into the mouse lungs through the trachea to establish the model, 50 μL / mouse (containing 5×106 conidia).
[0209] Trial drug: Itraconazole suspension for inhalation (Formulation D)
[0210] Grouping and dosing: The animals were randomly divided into 3 groups, with 12 animals in each group. Each dosing group was dosed from the day before modeling for 15 consecutive days (Day -1 to Day 13). Specific grouping and dosing information is shown in Table 13.
[0211] Table 13
[0212]
[0213] Detection indicators: During the experiment, the mice were weighed every day and general symptoms (including movement, mental state, fur, secretions, appetite, etc.) were observed; after modeling, the number of surviving mice in each group was recorded every day, and the survival rate was calculated (number of surviving individuals / total number of individuals × 100%), and the 4-day and 14-day survival rate curves were drawn ( Figure 7 ), some key test results are shown in Table 14.
[0214] Table 14 Survival rate of mice in each experimental group at 4 and 14 days
[0215]
[0216] Statistics: log-rank test, compared with the model group, * P < 0.01.
[0217] In summary of the experimental process, all mice in the model group died 4 days after modeling. Compared with the model group, the inhaled itraconazole group and the oral gavage itraconazole group could significantly increase the survival rate of mice at 4 days and 14 days (P < 0.01), and when the dose of itraconazole nebulized inhalation was 1 / 10 of the dose of oral gavage, the antibacterial effect was better than that of oral gavage.
Claims
1. A triazole drug suspension, comprising a therapeutically effective amount of itraconazole, a surfactant, a solvent, an osmotic pressure regulator, a metal complexing agent, and a pH regulator, wherein: The mass ratio of the itraconazole to the surfactant is 5:1 to 15:1; the particle size of the itraconazole is D 10 0.8~1.2μm, D 50 1.5~2.6μm, D 90 The concentration of free itraconazole in the suspension is 0.08 μg / ml~0.5 μg / ml; Wherein, the surfactant is Tween.
2. The suspension according to claim 1, wherein The mass ratio of the itraconazole to the surfactant is 8:1 to 12:
1.
3. The suspension according to claim 1 or 2, wherein The Tween is selected from one or more of Tween-20 and Tween-80.
4. The suspension according to claim 1 or 2, wherein The osmotic pressure regulator is sodium chloride or glucose.
5. The suspension according to claim 1 or 2, wherein The osmotic pressure regulator maintains the osmotic pressure molar concentration of the drug solution within the range of 260-330 mOsmol / kg.
6. The suspension according to claim 1 or 2, wherein The metal complexing agent is selected from disodium ethylenediaminetetraacetate, trisodium ethylenediaminetetraacetate, tetrasodium ethylenediaminetetraacetate, and calcium sodium ethylenediaminetetraacetate.
7. The suspension according to claim 6, wherein The metal complexing agent is disodium ethylenediaminetetraacetate.
8. The suspension according to claim 1 or 2, wherein The metal complexing agent is present in an amount of 0% to 0.02%, w / w, based on the total mass of the suspension.
9. The suspension according to claim 8, wherein The metal complexing agent is present in an amount of 0.008% to 0.012% (w / w) of the total mass of the suspension.
10. The suspension according to claim 1 or 2, wherein The pH adjuster is selected from NaOH / HCl, citric acid / sodium citrate and sodium dihydrogen phosphate / disodium hydrogen phosphate.
11. The suspension according to claim 10, wherein The pH adjuster is a combination of citric acid and sodium citrate.
12. The suspension according to claim 1 or 2, wherein The pH value of the itraconazole suspension is 5.5-6.
5.
13. The suspension according to claim 1 or 2, wherein The suspension is an itraconazole suspension for inhalation.
14. The suspension according to claim 13, wherein The itraconazole suspension for inhalation is used by using a nebulizer that generates aerosol using compressed air, ultrasonic waves or a vibrating mesh.
15. A method for preparing the triazole drug suspension according to any one of claims 1 to 14, the method comprising the following steps: (1) Take D 90 APIs with a diameter less than 10 μm; (2) dispersing the active ingredient itraconazole in the raw material drug prepared in step (1) in an aqueous solution containing part or all of the prescribed amount of a surfactant to prepare a main drug concentrated solution; (3) mixing the main drug concentrated solution prepared in step (2) with the auxiliary material solution to obtain a primary suspension; (4) Sterilize the initial suspension obtained in step (3); the F0 value should be ≥ 8 to obtain a sterile suspension; (5) dispersing the sterile suspension prepared in step (4) by high pressure homogenization, microfluidization or media grinding technology to obtain; In step (5), the homogenization pressure of the high-pressure homogenization is 700-1000 bar.
16. The method according to claim 15, wherein: In step (4), the sterilization conditions include sterilization at 121° C. for not less than 8 minutes.
17. The method according to claim 15, wherein: In step (4), the sterilization conditions include sterilization at 121° C. for 8-20 min.
18. The method according to claim 15, wherein: In step (4), the sterilization conditions include sterilization at 115°C for not less than 30 minutes.
19. Use of the triazole drug suspension according to any one of claims 1 to 14 or the triazole drug suspension obtained by the preparation method according to any one of claims 15 to 18 in the preparation of drugs for preventing and / or treating lung or respiratory diseases; in, The lung or respiratory disease is selected from one or more of pulmonary fibrosis, pulmonary aspergillosis, fungal sensitization to asthma, respiratory fungal infection, pulmonary fungal infection, fungal infection of organ transplantation or chronic idiopathic cough.
